Last updated: September 6, 2026
Indinavir sulfate is a mature HIV-1 protease inhibitor with negligible current commercial importance in high-income markets. Merck’s Crixivan franchise generated substantial revenue after its 1996 U.S. approval, but sales declined as combination therapy, dosing limitations, metabolic toxicity, and newer antiretroviral classes displaced the drug. Core patent protection has expired, U.S. branded marketing has ended, and current HIV treatment guidelines do not recommend indinavir as a preferred regimen.
What is the current market status of indinavir sulfate?
Indinavir sulfate occupies a residual market composed mainly of legacy treatment, limited generic supply, and selected lower-income-country procurement.
| Market factor |
Current assessment |
| Active ingredient |
Indinavir sulfate |
| Original brand |
Crixivan |
| Originator |
Merck & Co. |
| U.S. approval |
1996 |
| Therapeutic class |
HIV-1 protease inhibitor |
| Current guideline position |
Not preferred; generally avoided |
| U.S. branded commercial status |
No meaningful current franchise |
| Patent position |
Core patent protection expired |
| Biosimilar exposure |
None; indinavir is a small molecule |
| Generic exposure |
Technically high, commercially limited |
| Revenue visibility |
Minimal and generally not separately disclosed |
Indinavir was one of the first protease inhibitors to achieve broad commercial adoption. Its launch coincided with the expansion of highly active antiretroviral therapy, in which protease inhibitors were combined with nucleoside reverse transcriptase inhibitors. The drug became an important component of early combination regimens after its U.S. approval in 1996.[1]
The market later shifted toward once-daily, better-tolerated agents. Indinavir requires frequent dosing, substantial water intake to reduce nephrolithiasis risk, and careful management of food and drug interactions. These requirements materially reduced its competitiveness against newer protease inhibitors and, later, integrase strand transfer inhibitors.
How did Crixivan revenue change after launch?
Crixivan had a rapid commercial rise in the late 1990s, followed by a sustained decline as the HIV treatment market moved away from first-generation protease inhibitors.
Merck’s public filings reported Crixivan as a major product during the period immediately following launch. Sales reached the high hundreds of millions of dollars and approached or exceeded the billion-dollar range during the late 1990s, depending on the reporting year and product classification used in Merck’s annual reports.[2-4]
Revenue trajectory
| Period |
Commercial position |
Primary market drivers |
| 1996-1997 |
Rapid launch and uptake |
High unmet need and early combination therapy |
| 1998-2000 |
Peak commercial period |
Broad protease inhibitor use and limited competition from newer classes |
| 2001-2005 |
Decline begins |
Dosing burden, adverse effects, ritonavir-boosted alternatives |
| 2006-2012 |
Mature and shrinking product |
Expansion of once-daily and fixed-dose regimens |
| 2013 onward |
Residual market |
Generic or legacy use, limited commercial investment |
| Current period |
Commercially marginal |
Integrase inhibitor dominance and guideline exclusion |
Public company reporting became less useful for tracking indinavir after the product’s peak period because Merck reduced the level of product-specific disclosure as Crixivan became a smaller contributor to total pharmaceutical revenue. Current revenue attributable to indinavir sulfate is not generally reported as a material standalone figure.
The financial pattern is therefore a classic post-innovation decline: rapid initial uptake, a short peak period, erosion from therapeutic substitution, and eventual loss of strategic importance before patent expiry became the primary commercial event.
Why did indinavir lose market share?
Indinavir’s decline resulted from clinical and commercial disadvantages rather than a single competitor.
Dosing and administration limitations
The original regimen required 800 mg every eight hours, typically on an empty stomach, with significant fluid intake. The dosing schedule was less convenient than once-daily alternatives. Adherence was difficult, particularly for patients taking multiple antiretroviral agents.
Indinavir was also used with ritonavir boosting in later treatment practice. That approach increased pharmacokinetic complexity and added interaction management requirements.
Renal and metabolic toxicity
Indinavir is associated with nephrolithiasis, crystalluria, renal colic, and other renal complications. Patients require hydration and monitoring. The drug also carries class-related risks involving dyslipidemia, insulin resistance, lipodystrophy, and other metabolic effects.[1,5]
These concerns affected both physician preference and long-term treatment persistence.
Competition from newer HIV medicines
Indinavir competed first with other protease inhibitors, including lopinavir, atazanavir, and darunavir. It later faced stronger substitution from integrase inhibitors such as raltegravir, dolutegravir, and bictegravir.
Current treatment guidelines generally prioritize integrase inhibitor-based regimens because they offer better tolerability, fewer dosing constraints, improved interaction profiles, and high virologic efficacy.[5]
What is the FDA regulatory status of indinavir sulfate?
The FDA approved Crixivan capsules in 1996 for HIV-1 infection in adults. The product was approved as part of combination antiretroviral therapy rather than as monotherapy.[1]
The original U.S. label covered 200 mg and 400 mg capsules, with an adult dosage of 800 mg every eight hours. The label emphasized hydration and included warnings relating to nephrolithiasis, hematuria, crystalluria, and renal dysfunction.
Indinavir is not a biologic, so it does not face biosimilar competition. Any follow-on product would proceed through the abbreviated new drug application pathway as a generic small-molecule drug.
Current clinical positioning
The U.S. Department of Health and Human Services guidelines have moved indinavir out of preferred treatment and common alternative regimens. The drug may appear in historical treatment discussions or in limited circumstances involving treatment history, resistance, access constraints, or local procurement.[5]
That clinical status constrains market demand. Even if a manufacturer can obtain regulatory approval, physicians have little incentive to initiate new patients on indinavir when newer agents are available.
What patents protected Crixivan and when did indinavir lose exclusivity?
Indinavir’s principal compound protection expired years ago. The key U.S. patent family associated with the active pharmaceutical ingredient included U.S. Patent No. 5,413,999, which covered hydroxyethylamino sulfonamide compounds associated with Merck’s HIV protease inhibitor program.[6]
| IP category |
Indinavir position |
| Active-ingredient patents |
Expired |
| Core compound exclusivity |
Expired |
| U.S. data exclusivity |
Expired |
| Formulation protection |
Expired or commercially irrelevant |
| Method-of-use patents |
Expired or no longer commercially meaningful |
| Orange Book blocking position |
No current material barrier |
| Manufacturing know-how |
Potentially relevant for quality and cost, not market exclusivity |
The practical loss of exclusivity occurred during the 2010s at the latest, after the relevant patent terms had run and generic antiretroviral manufacturing had become established. Patent expiry did not produce a major U.S. generic wave because demand had already shifted to newer therapies.
Are formulation patents still commercially relevant?
No material formulation barrier remains for the standard capsule products. Any historical formulation or dosage patents would be expired, unenforceable against current commercial entry, or insufficient to support a meaningful branded premium.
The principal remaining barriers are commercial rather than patent-based:
- limited prescriber demand;
- low expected sales volume;
- procurement uncertainty;
- manufacturing economics;
- regulatory maintenance costs;
- competition from superior standard-of-care therapies.
What is the Orange Book status of indinavir sulfate?
Crixivan’s historical patents and regulatory listings are reflected in the FDA’s Orange Book records for the product. The commercial significance of those listings is now limited because the relevant exclusivity periods have ended and the branded product no longer has a defensible patent-based position.[7]
Orange Book status should be distinguished from market availability. A drug can remain in historical Orange Book records while having little or no active U.S. distribution. For indinavir, the relevant commercial question is not whether historical listings exist, but whether a manufacturer can justify maintaining an approved product for a shrinking patient population.
Are there Paragraph IV challenges to indinavir sulfate?
Paragraph IV litigation was not a major commercial driver for indinavir in the way it was for newer, higher-revenue medicines.
A Paragraph IV challenge requires a generic applicant to certify that a listed patent is invalid, unenforceable, or not infringed. For indinavir, the economic incentive to litigate was limited because:
- the market had already contracted sharply;
- the brand had lost clinical relevance;
- the remaining sales opportunity was small;
- the principal patent terms had expired;
- multiple newer HIV regimens had replaced the product.
The absence of a major modern Paragraph IV dispute does not indicate strong residual patent protection. It indicates that the expected return from challenging the product was low.
Which companies are challenging or competing with indinavir?
Indinavir no longer faces a conventional branded challenge centered on patent litigation. Its competitive set consists of therapies that replaced it clinically.
| Competitive category |
Examples |
Competitive effect |
| Other protease inhibitors |
Darunavir, atazanavir, lopinavir |
Better tolerability, potency, or dosing |
| Integrase inhibitors |
Dolutegravir, raltegravir, bictegravir |
Became preferred treatment class |
| Fixed-dose combinations |
Biktarvy, Triumeq, Dovato and others |
Improved adherence and convenience |
| Generic antiretrovirals |
Regional manufacturers |
Reduce price but do not restore demand |
| Long-acting therapy |
Cabotegravir-based regimens |
Further reduces relevance of older oral agents |
The strongest competitive pressure comes from integrase inhibitor-based products, not from another generic indinavir manufacturer. These regimens capture patients at treatment initiation and reduce the pool available for legacy protease inhibitors.
What generic launch risks exist for indinavir sulfate?
Generic entry risk is high from a legal perspective and low from a commercial displacement perspective.
A manufacturer could theoretically enter with capsules containing indinavir sulfate once it satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, chemistry, manufacturing, and controls. The principal commercial risks are more significant than the patent risks.
Generic business case
A generic manufacturer would face:
- a small addressable patient population;
- limited new-patient initiation;
- weak formulary incentives;
- low expected gross profit;
- potential supply-chain volatility;
- ongoing pharmacovigilance and quality obligations;
- competition from established HIV regimens with larger demand.
This explains why patent expiry did not lead to a large, highly visible U.S. generic market. Generic availability can exist without creating a commercially attractive product category.
Geographic coverage
Indinavir has had greater residual relevance in markets where:
- treatment budgets are constrained;
- older antiretroviral procurement contracts remain active;
- national formularies retain legacy medicines;
- access to integrase inhibitors is limited;
- local manufacturers produce older HIV medicines.
In the United States and Western Europe, the commercial market is effectively residual. In lower-income markets, availability depends on national procurement lists, donor programs, and manufacturer economics rather than patent barriers.
How strong is the indinavir patent estate?
The current patent estate is weak because the relevant exclusivity periods have expired.
| Patent-strength factor |
Assessment |
| Active compound protection |
No current blocking strength |
| Formulation protection |
No meaningful current barrier |
| Method-of-use protection |
No meaningful commercial barrier |
| Manufacturing IP |
May protect process efficiency or quality, not market access |
| Litigation leverage |
Minimal |
| Freedom-to-operate risk |
Low for standard generic manufacture, subject to jurisdiction |
| Commercial moat |
None |
Manufacturing know-how can still affect cost, yield, impurity control, and regulatory approval. It does not recreate the market protection once provided by compound patents.
What is the likely financial trajectory for indinavir sulfate?
The financial trajectory is stable at a low base rather than a recovery story.
Near-term outlook
Indinavir is unlikely to regain material revenue because the product lacks a clinical or commercial catalyst. A price increase could temporarily raise gross sales in a constrained market, but it would not create durable growth. Volume is limited by treatment guidelines and substitution into newer therapies.
Long-term outlook
The likely long-term pattern is:
- continued decline in branded revenue;
- sporadic generic or regional sales;
- possible supply interruptions as manufacturers reassess demand;
- further reduction in treatment use as older patients switch regimens;
- no meaningful patent-driven price premium.
Potential revenue exposure for Merck is immaterial relative to its current pharmaceutical portfolio. For a generic manufacturer, indinavir could provide a niche product line or procurement opportunity, but it is unlikely to support major investment in dedicated commercial infrastructure.
How does indinavir compare with newer HIV medicines?
| Attribute |
Indinavir sulfate |
Modern integrase inhibitor regimen |
| Dosing convenience |
Poor; historically every eight hours |
Often once daily |
| Hydration requirements |
Significant |
Generally no comparable requirement |
| Renal stone risk |
Established concern |
Usually lower for the regimen as a whole |
| Drug interactions |
Material |
Varies, often more manageable |
| Guideline position |
Not preferred |
Preferred in many settings |
| Patent status |
Expired |
Some products retain active patents |
| Commercial demand |
Residual |
Strong |
| Generic competition |
Possible but limited |
Increasing for older products |
| Investment outlook |
Low |
Higher, depending on product lifecycle |
Indinavir’s patent expiry does not make it a strong generic opportunity because the product has already lost therapeutic demand. Newer agents retain greater commercial value because clinicians and treatment programs select them for clinical performance, not because older products lack low-cost supply.
Key Takeaways
- Indinavir sulfate is a commercially mature HIV medicine with negligible current branded-market importance.
- Crixivan generated high hundreds of millions of dollars and approximately billion-dollar annual sales during its late-1990s commercial peak, according to Merck filings.
- Revenue declined as patients moved to better-tolerated protease inhibitors, fixed-dose combinations, and integrase inhibitor regimens.
- Core compound and formulation patent protection has expired.
- Current Orange Book records have limited practical commercial significance.
- Paragraph IV litigation has not been a major recent market event because the remaining opportunity is small.
- Generic entry is legally feasible but commercially unattractive in the United States.
- Indinavir has no biosimilar risk because it is a small-molecule drug.
- Residual demand is concentrated in legacy treatment and selected lower-income-country procurement markets.
- The financial outlook is continued low-volume erosion, not recovery.
FAQs
Is indinavir sulfate still used to treat HIV?
Yes, but infrequently. It may remain available for selected legacy patients or in markets with limited access to newer antiretrovirals. It is not a preferred first-line treatment in current U.S. guidelines.
Is Crixivan still sold in the United States?
Crixivan no longer has meaningful U.S. commercial presence. Historical regulatory records may remain, but branded availability and revenue are no longer material.
Can a generic manufacturer launch indinavir sulfate?
Yes. The relevant patent barriers have expired, but a manufacturer would still need FDA approval and a commercially viable supply strategy. The limited patient population makes U.S. launch economics weak.
Why did indinavir sales fall after early success?
Sales declined because the drug required frequent dosing, created hydration and renal-management burdens, caused metabolic and tolerability concerns, and was displaced by newer antiretroviral classes.
Does indinavir sulfate have any remaining patent value?
Its historical compound patent estate has no meaningful current blocking value. Manufacturing processes, quality controls, and regulatory know-how may retain operational value but do not support a significant exclusivity premium.
References
- U.S. Food and Drug Administration. (1996). Crixivan (indinavir sulfate) capsules: Prescribing information.
- Merck & Co., Inc. (1998). Annual report 1997.
- Merck & Co., Inc. (2000). Annual report 1999.
- Merck & Co., Inc. (2002). Annual report 2001.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
- U.S. Patent No. 5,413,999. (1995). Hydroxyethylamino sulfonamide compounds.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
